Free Smoking Cessation Program Now Available in Ireland

2Firsts Events by 2FIRSTS.ai
Jan.10.2024
Free Smoking Cessation Program Now Available in Ireland
HSE encourages smokers to quit by offering free smoking cessation aids including nicotine replacement therapy.

According to a report by Irish media outlet Limerick Post at a certain time, the Irish Health Service Executive (HSE) is actively encouraging people who quit smoking by offering them free smoking cessation aid packages.

 

A spokesperson from the health service department stated, "Many individuals attempting to quit smoking do not receive the necessary support and treatment methods, such as smoking cessation medications, that provide the greatest chances of success. HSE is here to help you quit smoking by offering free nicotine replacement therapy (NRT) along with other tried and tested support options.

 

The smoking cessation service provided by the HSE is free throughout the year and offers personalized, evidence-based plans tailored to individual needs. It provides a range of support options, which can be combined according to individual preferences, such as:

 

Online personalized quit smoking program tracks its progress; face-to-face and group support from the community; SMS or telephone support available through the toll-free line 1800 201 203; free "Quit Smoking Kit" to aid in preparation for quitting; free provision of nicotine replacement therapy (NRT) with usage guidance; daily advice and support from individuals who have successfully quit smoking or are currently attempting to quit on the "You Can Quit Smoking" Facebook page.

 

The Health and Safety Executive (HSE) recommends several strategies for quitting smoking. These include seeking support from others, including HSE's smoking cessation services, rather than fighting the battle alone. The advice is to focus on maintaining a smoke-free status every day until reaching the milestone of 28 days, as this significantly increases the chances of quitting permanently. Additionally, the use of smoking cessation medications such as Nicotine Replacement Therapy (NRT) is suggested as a safe, effective, and clinically viable method to overcome initial cravings and navigate the first 28 days of quitting.

 

Dr. Paul Kavanagh, the Public Health Medicine Advisor in charge of Ireland's Smoke-Free Plan, has clarified that Nicotine Replacement Therapy (NRT) is both safe and effective. "We know that NRT is very safe and also effective," he said. These medications are strictly regulated by the Irish Health Products Regulatory Authority (HPRA).

 

We are encouraged to see an increasing number of smokers using NRT to help them quit smoking. We have been making efforts to improve the accessibility and availability of this life-saving medication. Smokers, those looking to quit, and the healthcare professionals supporting them can have full trust and confidence in the safety and effectiveness of NRT.

 

Some smokers may be curious about using e-cigarettes or e-liquid to help them quit smoking. We do not have sufficient trust and confidence in the safety and efficacy of e-cigarettes as a means of quitting smoking, so we recommend using NRT to assist them in their quit attempts.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24
Senate Democrat Wyden Probes Trump Administration Vape Policy Shift, Seeks Records From HHS and Reynolds American
Senate Democrat Wyden Probes Trump Administration Vape Policy Shift, Seeks Records From HHS and Reynolds American
U.S. Senator Ron Wyden, the Democratic ranking member of the Senate Finance Committee, has launched an investigation into flavored vape policy changes and requested records from the Department of Health and Human Services (HHS), Reynolds American and Botanic Tonics. The investigation focuses on a timeline involving Reynolds American’s $5 million donation to MAGA Inc. in April 2026 and subsequent vape policy developments. Wyden said the review aims to examine potential links between political donations, corporate communications and government decisions. The investigation does not represent a finding of wrongdoing.
Innovation
Aug.07 by 2Firsts Perspectives
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
China STMA Deputy Administrator Meets KT&G COO as Heated Cigarette Rules Advance
China STMA Deputy Administrator Meets KT&G COO as Heated Cigarette Rules Advance
Wang Gongcheng, deputy administrator of China’s State Tobacco Monopoly Administration, met KT&G Chief Operating Officer Lee Sang-hak in Shanghai on September 1, according to Oriental Tobacco News. The meeting comes as China seeks public comment on a draft mandatory national standard for heated cigarettes. The report did not disclose the subjects discussed or indicate whether heated tobacco products or market access were addressed.
News
Sep.02